INTRODUCTION 33
Tissue-specific loss-of-function (LOF) analysis is instrumental for elucidating the developmental roles 34 of essential genes, determining cell autonomy, and dissecting cell-cell interactions. Conventional 35 methods for studying tissue-specific gene function in Drosophila, such as mosaic analysis with a 36 repressible cell marker (MARCM) 1 and tissue-specific RNA interference (RNAi) 2, 3 , are powerful 37 approaches for genetic screens and LOF analysis. However, these techniques present several 38 disadvantages. RNAi is prone to off-target effects 4 and gene knockdown is rarely complete 2 because this 39 technique only targets mRNAs for degradation or translational suppression. MARCM produces more 40 reliable LOF of genes of interest, but the process can be labor intensive and requires multiple 41 components to be combined in the same animal. 42
The CRISPR/Cas9 system 5 has the potential to surpass the current methods of tissue-specific 43 LOF in Drosophila due to its simplicity and efficiency in creating gene disruption [6] [7] [8] [9] [10] [11] . In this system, 44
Cas9 endonuclease cleaves double-stranded genomic DNA at a site determined by the protospacer 45 sequence (or targeting sequence) of a chimeric guide RNA (gRNA) 5 . Cas9-mediated double-stranded 46 breaks (DSBs) at the targeting site are then repaired by the host through either nonhomologous end 47 joining (NHEJ) or homology-directed repair (HDR) 12 . Imprecise repair through NHEJ can result in 48 small insertions or deletions (indels) at a single target site 6 or deletions of DNA fragments between two 49 target sites 9, 10 . CRISPR/Cas9 has been successfully used in Drosophila and other organisms to create 50 heritable mutations [6] [7] [8] , to edit genomic sequences precisely 13, 14 , and to control gene expression 15, 16 . 51
Conditional mutagenesis of genes has been achieved in Drosophila by combining the 52 CRISPR/Cas9 system with the Gal4/UAS system [17] [18] [19] . In this approach, tissue-specific Gal4 drives UAS-53
Cas9 expression, while gRNAs are expressed either from ubiquitous promoters 17, 18 or by UAS 19 . 54
Transgenic constructs expressing multiple gRNAs increase mutagenesis efficiency and allow 55 simultaneous mutagenesis of more than one gene [17] [18] [19] . Despite these initial successes, Gal4-driven Cas9 56 and transgenic gRNAs have not been widely used to study tissue-specific gene function due to 57 uncertainties and limitations associated with this method. For example, gRNAs can vary greatly in their 58 mutagenic efficiency, and it is difficult to know whether a transgenic gRNA reliably causes mutations in 59 the tissue of interest. These concerns worsen when a multiplex gRNA construct is used to knock out two 60 or more genes simultaneously. Gal4-driven Cas9 has several additional potential drawbacks that could 61 limit its applications in developmental studies. First, the intermediate Gal4 expression step can delay 62 Cas9 expression, making it difficult to study early gene functions in specific tissues. Second, the 63 Gal4/UAS system often results in excessive levels of Cas9 expression which can be toxic 20 . Finally, 64 using Gal4-driven Cas9 makes the Gal4/UAS system unavailable for other genetic manipulations in the 65 same animal. Thus, a simpler and more robust method of tissue-specific mutagenesis is needed to take 66 full advantage of the CRISPR/Cas9 system. 67
One way to improve conditional mutagenesis is optimization of transgenic gRNAs. The 68 mutagenic efficiency of a gRNA is affected by both the gRNA target sequence and the transgenic vector 69 design. Previous studies in Drosophila exploring choices of the gRNA promoter, the length and 70 sequence composition of the target sequence, and methods of producing multiple gRNAs from a single 71 construct have identified several parameters for making efficient gRNAs [17] [18] [19] 21 . However, the goal of 72 most of these strategies was to increase the frequency of heritable mutations, leaving room for 73 optimization of transgenic gRNA design for mutagenesis in somatic cells. In addition, specific 74 modifications of the gRNA scaffold improve Cas9 targeting to DNA in human cells 22 , but these 75 modifications have not been tested to date in Drosophila. Thus, there is a compelling need for optimized 76 transgenic gRNAs coupled with tissue-specific control of Cas9 efficacy. 77
Here, we have developed a new CRISPR/Cas9 toolkit that achieves highly efficient knockout of 78 one or multiple Drosophila genes in a tissue-specific manner. Our method of CRISPR-mediated tissue-79 restricted mutagenesis (CRISPR-TRiM) (Fig. 1a) combines a transgenic Cas9 driven by a tissue specific 80 enhancer with a transgenic construct that ubiquitously expresses multiple gRNAs. By targeting every 81 gene of interest with two gRNAs, this system mutates all target genes tissue-specifically through indel 82 formation or large DNA deletions. To build the most efficient reagents, we have generated convenient 83 tools for making and evaluating enhancer-driven Cas9 transgenes, identified a multi-gRNA design that 84 is superior to previous options, and established an in vivo assay for testing gRNA efficiency in causing 85 DSBs. We investigated how the frequency of DNA deletion in individual somatic cells is impacted by 86 the distance between two target sites and we further found that enhancer-driven Cas9 is more effective 87 in causing LOF and less cytotoxic than Gal4-driven Cas9. Using genes in the SNARE (soluble N-88 ethylmalemide-sensitive factor attachment protein receptor) pathway as examples, we demonstrate here 89 that CRISPR-TRiM can efficiently knock out multiple redundant genes in neurons. Our results also 90 underscore the importance of mutagenesis timing for uncovering tissue-specific gene functions: Post-91 mitotic knockout of neuronal type-specific genes, such as the receptor protein tyrosine phosphatase 92
Ptp69D, is sufficient and effective for removing gene functions; while housekeeping genes, such as 93 those encoding NSF and SNAP proteins, require mutagenesis earlier in the cell lineage to unmask their 94 LOF phenotypes. 95
RESULTS

96
Generation and evaluation of tissue-specific Cas9 lines 97
Our CRISPR-TRiM strategy (Fig. 1 ) relies on the availability of efficient tissue-specific Cas9 98 transgenes. To simplify the generation of tissue-specific Cas9 lines, we developed a Cas9 Gateway 99 destination vector pDEST-APIC-Cas9 using the pAPIC (attB P-element insulated CaSpeR) backbone 23 100 (Fig. 2a) . Tissue-specific enhancers can be conveniently swapped into this vector through the Gateway 101 LR reaction to generate Cas9-expression constructs. This cloning strategy is compatible with over 102 14,000 FlyLight (Table S1 ). The positive tester ubiquitously expresses Gal80, Gal4, and 117 two gRNAs targeting Gal80; and it also contains a UAS-driven GFP (Fig. 2b) . In cells that do not 118 express Cas9, Gal80 suppresses Gal4 activity, thereby inhibiting GFP expression. In contrast, in Cas9-119 expressing cells, the gRNAs induce mutations in Gal80 and thus allow Gal4-driven GFP expression. As 120 examples, we generated random insertions of ppk-Cas9 and hh-Cas9 and evaluated their tissue 121 specificities using the positive tester. The ppk enhancer is specific to class IV dendritic arborization 122 (C4da) sensory neurons growing on the larval body wall 31 , while the R28E04 enhancer of hh drives 123 epidermal expression in the posterior half of every hemisegment (http://flweb.janelia.org). The positive 124 tester allowed us to identify the ppk-Cas9 and hh-Cas9 insertions that most resemble the expected 125 patterns ( Fig. 2c and d) . 126
Negative testers help further evaluate the efficiency of Cas9 transgenes in inducing mutations. A 127 negative tester contains a ubiquitous or tissue-specific Gal4, a UAS-driven cytosolic or membrane GFP, 128 a UAS-driven nuclear RFP, and two ubiquitous gRNAs targeting GFP (Fig. 2b) . With a negative tester, 129 cells that do not express Cas9 are dually labeled by both GFP and the nuclear RFP. In contrast, Cas9-130 expressing cells are only labeled by the nuclear RFP, due to GFP mutagenesis. When crossed to negative 131 testers ubiquitously expressing Gal4, hh-Cas9 as expected caused loss of GFP in the posterior 132 compartments of larval epidermal segments (Fig. 2e ) and imaginal discs (Fig. 2f) . A neuronal negative 133 tester expressing the membrane marker CD8-GFP in all da neurons (NT3) showed that ppk-Cas9 134 specifically knocked out GFP in C4da neurons (Fig. 2g) . Negative testers are particularly useful for 135 comparing the efficiency of Cas9 lines in mutagenesis: Lower persistent GFP signals likely reflect 136 earlier-acting Cas9. Using NT3, we detected small but consistent differences among three efficient ppk-137
Cas9 insertions (Fig. 2i) , with two insertions (ppk-Cas9 ). In comparison, Cas9 driven by a pan-da RluA1 enhancer is less efficient in mutating GFP 139 (Fig. 2h ), leading to higher and variable levels of remaining GFP in C4da neurons (Fig. 2i) . 140
The Cas9 Gateway cloning vector and the Cas9 tester lines together provide a convenient 141 toolbox for generating and identifying Cas9 transgenes that are most efficient for CRISPR-TRiM. 142
Optimization of multi-gRNA design for tissue-specific gene knockout in Drosophila 143
Being able to express multiple gRNAs from a single transgenic construct is desirable for CRISPR-144
TRiM, as more gRNAs can increase the chance of LOF in a single gene and also enable simultaneous 145 mutagenesis of multiple genes [17] [18] [19] . A common strategy for making multiplex gRNA constructs in 146 Drosophila is to use two or three ubiquitous U6 promotors in tandem, each driving a gRNA separately 18 . 147
For this purpose, U6:1 and U6:3 promoters have been found to drive high gRNA expression 18 . 148
Alternatively, polycistronic gRNA designs with intervening tRNA sequences have also been reported to 149 be effective in expressing multiple gRNAs in plants and Drosophila 19, 32 . We wished to optimize the 150 multi-gRNA strategy to achieve the greatest mutagenic efficiency in somatic cells. We thus compared 151 four dual-gRNA designs that carry the same two targeting sequences for GFP (Fig. 3a) . These constructs 152
were made with a P-element/attB dual transformation vector that uses mini-white as the selection 153 marker. Three of them (forward, reverse, and insulated) are variants of a U6:1-gRNA-U6:3-gRNA 154 strategy described previously . We found that the performance of gRNAs based on U6:1-gRNA-U6:3-gRNA varied 165 greatly for the same neuron and that none of these designs are efficient enough to remove GFP in all 166 neurons (Fig. 3c) . In contrast, the tgFE design was far superior, with near complete elimination of GFP 167 signals in almost all neurons examined (Fig. 3c) . Because previous studies indicated that the use of 168 tRNA in polycistronic gRNAs does not seem by itself to enhance mutagenesis 19 , we think the tgFE 169 design's high efficiency is likely due to the F+E gRNA scaffold. An additional benefit of the tgFE 170 strategy is the convenient cloning of 2-6 gRNAs in a single step. 171
Efficiency of dual gRNA-mediated DNA deletion at the single cell level 172
When using two gRNAs to target the same gene, Cas9-mediated DSBs can result in indels at both target 173 sites, or large DNA deletions between the two target sites 9 . Deletion of a larger piece of DNA is more 174 likely to generate a null allele. To investigate the frequency of large deletions caused by two gRNAs in 175 individual cells, we constructed a reporter nSyb-tdGFP ("td" standing for tandem dimer) (Fig. 4a) that 176 labels all 12 neurons in the dorsal cluster of PNS sensory neurons (Fig. 3b, 4b ). In addition, we designed 177 7 gRNAs (0 to 6) targeting different sites in the non-coding sequence of this reporter, with site 0 located 178 before the nSyb enhancer, site 1 immediately after the enhancer, and the remaining sites at various 179 distances downstream of the tdGFP coding sequence (Fig. 4a) . We reasoned that small indels at any of 180 these target sites would be unlikely to abolish GFP expression, but large deletions between site 0 and 181 any of the other targeting sites would (Fig. 4c) . As a control, we included a gRNA pair that targets two 182 sites in the tdGFP coding sequence (gRNA-GFP) and therefore is predicted to remove GFP expression 183 by either indels or large deletions. 184
Using a strong and ubiquitously expressed Act-Cas9
18
, we tested the efficiencies of these gRNA 185 pairs in eliminating GFP expression in individual neurons with two different nSyb-tdGFP insertions. In 186 all animals examined, gRNA-GFP completely abolished GFP expression as expected (Fig. 4d, e) , 187 demonstrating the efficiency of DSB-mediated mutagenesis. Unexpectedly, gRNA 0 alone reduced 188 numbers of labeled neurons in some animals (reduction mean±SD: 19.8%±15.7% for attP (Fig. 4c-e) . These data suggest that large deletions occur in 194 random somatic cells and that an inverse correlation exists between deletion frequency and gRNA 195 distance. Importantly, our results suggest that large deletions do not occur frequently enough to remove 196 gene function in every cell such that indels in the coding region are more reliable for causing LOF. 197 Enhancer-driven Cas9 is advantageous over Gal4-driven Cas9 for studying neural development 198
Conditional mutagenesis can be achieved in Drosophila somatic cells using Gal4-driven Cas9 [17] [18] [19] , but 199 this method requires an intermediate transcription step that could potentially delay Cas9 expression. 200
Consistent with this assumption, ppk-CD4-tdGFP is expressed at least 8 hours earlier than UAS-CD8-201
GFP driven by ppk-Gal4 in the embryo 23 . Thus, we predict that enhancer-driven Cas9 will result in 202 earlier Cas9 action, thereby reducing perdurance of wildtype mRNA or protein products of the target 203 gene made prior to mutation induction. We tested this hypothesis by comparing the effectiveness of 204 enhancer-driven Cas9 and Gal4-driven Cas9 in knocking out CD4-tdGFP expression in C4da neurons 205 (Fig. 5a ). We observed more consistent and stronger reduction of GFP with ppk-Cas9 insertions 206 compared to ppk-Gal4 UAS-Cas9 (ppk>Cas9) (Fig. 5b) , although these differences were not statistically 207 significant with our sample sizes. To ask whether even earlier Cas9 expression could lead to further GFP 208 reduction, we made an enhancer-driven Cas9 that is expressed in sensory organ precursors (SOPs), the 209 progenitor cells of da neurons 35 . Indeed, SOP-Cas9 resulted in complete loss of GFP fluorescence in 210 most animals (Fig. 5b) . 211
High levels of Cas9 have been reported to be cytotoxic 20 . Consistent with our supposition that 212 Gal4-driven Cas9 generally produces more Cas9 protein than enhancer-fusion versions, we found that 213 ppk>Cas9 caused obvious dendrite reduction in C4da neurons even in the absence of gRNAs while ppk-214
Cas9 lines had much weaker impacts on dendrite morphology (Fig. 5c-e, g ). These data suggest that 215 high levels of Cas9 in post-mitotic neurons are not desirable for studying neuronal morphogenesis and 216 that enhancer-driven Cas9 could alleviate this concern. 217
We also compared the effects of RNAi-mediated suppression of GFP expression and 218 CRISPR/Cas9-induced GFP mutagenesis. CD4-tdGFP was knocked down with a publicly available 219
UAS-GFP-RNAi line 36
driven by ppk-Gal4. We also co-expressed Dicer-2 (Dcr-2) in C4da neurons to 220 enhance double strand RNA (dsRNA)-mediated mRNA knockdown 2 . RNAi was found to be less 221 efficient in eliminating GFP than CRISPR-mediated mutagenesis by either enhancer-driven Cas9 or 222
Gal4-driven Cas9 (Fig. 5b) . In addition, we found that Dcr-2 overexpression, which is commonly 223 employed in Drosophila RNAi experiments, caused an even stronger dendrite reduction than ppk>Cas9 224 (Fig. 3f, g ), indicating that Dcr-2 also has cytotoxicity in neurons. 225
Our results suggest that enhancer-driven Cas9 outperforms Gal4-driven Cas9 in tissue-specific 226 mutagenesis and that the CRISPR-TRiM method is more effective than RNAi in LOF studies. 227 To validate the efficiency of gRNA-Ptp69D, we established a "Cas9-LEThAL" (for Cas9-237 induced lethal effect through the absence of Lig4) assay (Fig. S2 ) that was adapted from a previously 238 described method for assessing injection-based gRNA efficiency 38 . Efficient gRNAs for non-essential 239 genes, such as a published gRNA for e 18 (Table S2) , cause male-specific lethality in pupal stages when 240 males carrying gRNAs are crossed to Act-Cas9 lig4 homozygous females. But if the target gene is 241 essential, in the same cross, efficient gRNAs should cause lethality of both males and females similar to 242 homozygous mutants. gRNA-Ptp69D caused all animals to die at late pupal stages in this assay, 243
Post-mitotic knockout of Ptp69D reveals its function in C4da neurons
indicating that this gRNA line is efficient (Table S2) . 244
We knocked out Ptp69D in C4da neurons using both ppk-Cas9 and SOP-Cas9. (Fig. 6a-d) . In both cases, the extent of dendrite 250 reduction caused by CRISPR-TRiM were also similar to that in Ptp69D 14 / Df(3L)8ex34 hemizygous null 251 mutant larvae 37 (Fig. 6e, f) . These data suggest that post-mitotic mutagenesis is sufficient to remove 252
Ptp69D gene function, which is consistent with Ptp69D being a neuronal type-specific transmembrane 253 To conduct CRISPR-TRiM analyses, we used the tgFE design to generate dual-gRNA constructs 268 for every NSF and SNAP.b gene. Also using the tgFE design, we made 4-gRNA constructs to knock out 269 Nsf1/Nsf2 simultaneously and Snap24/Snap25 simultaneously, and a 6-gRNA construct to knock out all 270 three SNAP.b genes. The efficiencies of these gRNA lines were first validated with the Cas9-LEThAL 271 assay (Table S2) advanced the lethal phase to late embryos, suggesting that Snap29 is also redundant with Snap24 and 280
Snap25. 281
We knocked out NSF and SNAP.b genes in C4da neurons using both ppk-Cas9 and SOP-Cas9. 282
Removing individual NSF genes did not cause obvious dendritic reductions (Fig. S1a-c, h-j) , but 283 surprisingly SOP-Cas9/gRNA-Nsf2 neurons instead showed a mild but consistent increase of dendrite 284 length and density (Fig. 7g-h,) . Knocking out both Nsf1 and Nsf2 using ppk-Cas9 produced weak and 285 variable C4da dendrite reduction (Fig. 7a, b, g-h) , while SOP-Cas9/gRNA-Nsf1-Nsf2 animals showed 286 stronger and more consistent dendrite reductions (Fig. 7e, g-h) . These data suggest that Nsf1 and Nsf2 287 act redundantly to promote dendrite growth. Furthermore, the observation that SOP-Cas9 caused a 288 stronger phenotype than ppk-Cas9 suggest that NSF gene products made in sensory organ precursors are 289 not sufficient to support dendrite growth but those made at the time of post-mitotic mutagenesis allow 290 neurons to grow a significant amount of dendrites. 291
Tissue-specific knockout of individual SNAP.b genes using ppk-Cas9 or SOP-Cas9 produced 292 either no obvious phenotypes (for Snap24 and Snap25) or weak dendrite reductions (for Snap29) (Fig. 293 S1d-f, k-m). Knocking out both Snap24 and Snap25 similarly did not cause obvious dendrite defects 294 (Fig. S1g, n) , which is somewhat surprising considering that Snap24 and Snap25 play redundant roles in 295 synaptic transmission at neuromuscular junctions (NMJs) 45 . We next knocked out all three SNAP.b 296 genes using gRNA-Snap24-Snap25-Snap29. While ppk-Cas9-mediated knockout only slightly reduced 297 dendrite density (Fig. 7c, g-h) , SOP-Cas9-mediated knockout caused strong C4da dendrite reduction and 298 degeneration (n=16/19 neurons) in second instar larvae (Fig. 7f) and late larval lethality. Although SOP-299
Cas9 is highly efficient in da neurons as shown by the NT3 negative tester (Fig. S1o) , this lethality 300 might be independent of neuronal defects, because SOP-Cas9 also labeled a small number of random 301 larval epidermal cells with the positive tester (Fig. S1p) . Nevertheless, our results suggest that, like NSF 302 genes, all three SNAP.b genes are redundantly required in C4da neurons and that mutagenesis before the 303 neuronal birth is required to unmask the LOF phenotype of SNAP.b genes. 304
As the SNARE machinery is required for all vesicle trafficking in the cell, we were curious why 305 knocking out all NSF or all SNAP.b genes in neurons with SOP-Cas9 was not sufficient to suppress all 306 dendritic growth. One possibility is that membrane trafficking-independent mechanisms exist that allow 307 neurons to elaborate dendrites. Alternatively, NSF and SNAP.b gene products contributed maternally or 308 made before SOP-Cas9 activity persist long enough to support a small degree of larval dendrite growth. 309
To distinguish between these possibilities, we turned to adult C4da neurons. C4da neurons ddaC and 310 v'ada prune all their dendrites during metamorphosis and regrow new dendritic arbors in late pupae 46 . 311
Because dendritic pruning removes all existing gene products except for the residual amounts left in the 312 cell body, dendrite regrowth must rely on new transcription. If NSF and SNAP.b genes are required for 313 all dendrite growth, knocking out all NSF or SNAP.b genes during larval stages should prevent dendrite 314 regrowth. Indeed, adult v'ada neurons lacking Nsf1 Nsf2 or Snap24 Snap25 Snap29 via ppk-Cas9-315 mediated knockout either did not regrow primary branches or showed severe reduction in total dendrite 316 length (Fig. 7i-l) . These data suggest that ppk-Cas9 can effectively remove redundant genes in post-317 mitotic neurons and that neuronal dendrite growth absolutely requires SNARE function. 318
In this study, we describe an optimized strategy we call CRISPR-TRiM for tissue-specific gene 321 mutagenesis using CRISPR/Cas9 in Drosophila. To implement this method, we developed a toolkit for 322 generating and evaluating enhancer-driven Cas9 lines, created convenient cloning vectors for making 323 efficient multi-gRNA transgenes, and established an assay for assessing the mutagenic efficiency of 324 transgenic gRNAs. Using our CRISPR-TRiM tools, we demonstrate that post-mitotic knockout of 325
Ptp69D causes efficient LOF in neurons, while SNARE complex components are strongly redundant 326 and perdurant in supporting neuronal dendrite development. 327
Comparison of CRISPR-TRiM with other tissue-specific LOF methods 328
Flp/FRT-based mosaic analyses have been widely used for investigating tissue-specific roles of genes in 329
Drosophila
47
. Among these techniques, MARCM and its variants are considered gold standards for 330 neuronal studies due to the positive labeling of homozygous mutant cells and the single cell resolution 331 they offer 1, 48 . However, MARCM and other Flp/FRT-based mosaic analyses also have some obvious 332 limitations. First, they require preexisting mutations in the gene of interest recombined with FRT on the 333 appropriate chromosome arm. Second, because these techniques rely on mitotic chromosome crossovers 334 which would result in wildtype "twin spots", it is impossible to remove gene function in every cell of the 335 tissue of interest. Third, these techniques require at least five genetic components in the final genotype, 336 making it harder to introduce additional components. Lastly, generating cells mutant for multiple genes 337 located on different chromosome arms is extremely difficult, if not impossible. In contrast, the bipartite 338 CRISPR-TRiM system requires only transgenic components that are independent of all existing binary 339 expression systems. Using efficient Cas9 and gRNA reagents, LOF in all cells of the target tissue can be 340 expected. These features make CRISPR-TRiM much more convenient than traditional mosaic-based 341 methods. 342
Compared to UAS-Cas9 driven by tissue-specific Gal4s, our CRISPR-TRiM system has the 343 advantages of faster Cas9 expression (and therefore more complete LOF) and decreased cytotoxicity due 344 to lower Cas9 expression levels. An additional benefit of using enhancer-driven Cas9 in CRISPR-TRiM 345 is that the Gal4/UAS system is available for other genetic manipulations in the same experiment. 346
In the last decade, several genome-wide UAS-RNAi resources have greatly accelerated gene 347 identification and characterization in Drosophila Designing efficient gRNA constructs and assessing gRNA efficiency 369
Our comparison of several dual-gRNA designs using the same targeting sequences revealed that the 370 tgFE design is particularly efficient for mutagenesis in larval sensory neurons. We found that the same 371 design also performs well in other somatic tissues (data not shown). The tgFE design combines tRNA-372 processing for releasing multiple gRNAs from a single transcript 19, 32 and F+E modifications that consist 373 of an A-U flip and a hairpin extension in the gRNA scaffold 22 . We consider this design the most 374 significant improvement for our CRISPR-TRiM system. This design may also work well in the germ 375 line for creating heritable mutations. 376
Although large deletions induced by two gRNAs would be more effective in causing LOF, we 377 found that the frequency of large deletions in somatic cells is too low to be reliable. Therefore, to 378 maximize the chance of LOF mutagenesis, we recommend selecting targeting sites in coding sequences 379 shared by all protein isoforms, preferably in conserved protein domains. In our experience, choosing 380 common top hits by using multiple experimentally-validated gRNA selection algorithms 49, 52, 53 usually 381 yield very efficient gRNAs. 382
We also recommend evaluating the in vivo efficiency of gRNA lines using the Cas9-LEThAL 383 assay before conducting CRISPR-TRiM analyses. In our hands, the lethal phase of male progeny in this 384 assay reliably indicates gRNA efficiency for our CRISPR-TRiM experiments. 385
Using CRISPR-TRiM to study neuronal morphogenesis 386
We provide two examples of CRISPR-TRiM analysis in C4da neurons. Our results show that the timing 387 of mutagenesis and the perdurance of gene products influence the extent of LOF; therefore, these 388 parameters must be considered when choosing the most appropriate Cas9 line. The CRISPR-TRiM 389 analysis of Ptp69D shows that post-mitotic mutagenesis is sufficient to cause its LOF, because Ptp69D 390 either is expressed late in neuronal development or turns over quickly. In contrast, SNARE components 391 are made early in the neuronal lineage and are highly perdurant. The early-acting SOP-Cas9 therefore is 392 required to reveal SNARE LOF phenotypes in neurons. Moreover, we found that dendrite regrowth of 393 adult C4da neurons provides an opportunity to unmask fully the requirements of SNARE components 394 for dendrite morphogenesis. This technique should be useful for circumventing potential perdurance 395 because gene products are removed by dendrite pruning prior to the regrowth. Our results imply that 396 perdurance could be an underappreciated concern for studying development roles of housekeeping genes 397 in any mutation-based LOF analysis. In summary, we present an optimized system for generating tissue-specific gene knockout using 410 CRISPR/Cas9. The tools we developed can be applied to address a broad range of developmental, cell 411 biological, and physiological questions in Drosophila. 412 
METHODS
413
FIGURE LEGENDS 565
